Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant MesoPher dendritic cell immunotherapy after CRS-HIPEC for malignant peritoneal mesothelioma
NL-OMON48572Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MesoPher in peritoneal mesothelioma, sponsored by Erasmus MC. Primary endpoint: Feasibility of adjuvant DCBI with MesoPher after CRS-HIPEC. Started Mar 2018; status: active, not recruiting.
02
Drugs
MesoPher
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NL-OMON48572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48572.